WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR), a biopharmaceutical company, published preclinical data on its lead immuno-oncology candidate, NKTR-214, bempegaldesleukin (bempeg), an investigational CD122-preferential interleukin-2 pathway agonist designed to provide activation and proliferation of cancer-killing immune cells. The company said the data showed that bempeg, in combination with immune-based therapies including checkpoint inhibition, antigen-specific vaccination and adoptive cell transfer therapy, enhanced T-cell mediated tumor control.
Bempeg in combination with checkpoint inhibitors and other immune-mediating agents is being evaluated in clinical trials, Nektar Therapeutics noted.
Copyright RTT News/dpa-AFX
© 2020 AFX News
